Condition: Ovarian Neoplasm Epithelial · Fallopian Tube Neoplasms · Peritoneal Neoplasms · Sponsor: Swiss GO Trial Group
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo. The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).
This description comes directly from the study's public registry record.
McLaughlin, PhD · +41 61 328 42 04 · mclaughlin@swiss-go.ch
Vogel, PhD · +41 61 3284203 · vogel@swiss-go.ch
Always discuss trial participation with your own doctor first.
| Krankenhaus der Barmherzigen Brüder Graz | Graz, Austria | Recruiting |
| Medizinische Universität Graz | Graz, Austria | Recruiting |
| Medizinische Universität Innsbruck | Innsbruck, Austria | Recruiting |
| Landeskrankenhaus Hochsteiermark Leoben | Leoben, Austria | Recruiting |
| Ordensklinikum Linz Barmherzige Schwestern | Linz, Austria | Recruiting |
| Universitätsklinikum Salzburg | Salzburg, Austria | Recruiting |
| Medizinische Universität Wien | Vienna, Austria | Recruiting |
| Klinik Hietzing Wien | Vienna, Austria | Recruiting |
| Charité - Universitätsmedizin Berlin Campus Virchow Klinikum | Berlin, Germany | Recruiting |
| St. Elisabeth-Krankenhaus | Cologne, Germany | Recruiting |
| Donauisar Klinikum | Deggendorf, Germany | Recruiting |
| Universitätsklinikum Carl Gustav Carus Dresden | Dresden, Germany | Active Not Recruiting |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04111978